1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended June 30, 2022.
+Added: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended September 30, 2022.
Refer to Part I, Item 2.
6 unchanged sentences
Total 1,496,661 (a)
+Added: 1,494,017 (a)
(a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
1 unchanged sentence
10.1 Modification No.
−Removed: 0 5 to Project Agreement, dated as of March 22, 2022 , by and between Regeneron Pharmaceuticals, Inc.
+Added: 02 to Base Agreement, dated as of August 2, 2022, by and between Regeneron Pharmaceuticals, Inc.
(the "Registrant") and Advanced Technology International.
−Removed: 10.2* Amended and Restated Immuno-Oncology License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant and Sanofi Biotechnology SAS.
−Removed: 10.3* Fifth Amendment to Amended and Restated License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi.
+Added: 10.2* Modification No.
+Added: 03 to Project Agreement, dated as of May 21, 2021, by and between the Registrant and Advanced Technology International.
+Added: 10.3 Modification No.
+Added: 04 to Project Agreement, dated as of July 12, 2021, by and between the Registrant and Advanced Technology International.
+Added: 10.4* Modification No.
+Added: 06 to Project Agreement, dated as of July 12, 2022, by and between the Registrant and Advanced Technology International.
+Added: 10.5* Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S.
+Added: Army Contracting Command, New Jersey.
+Added: 10.6* Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S.
+Added: Army Contracting Command, New Jersey.
+Added: 10.7 Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S.
+Added: Army Contracting Command, New Jersey.
+Added: 10.8* Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S.
+Added: Army Contracting Command, New Jersey.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
3 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the Registrant's Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021;
−Removed: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2022 and 2021;
−Removed: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2022 and 2021;
−Removed: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021;
+Added: (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021;
+Added: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2022 and 2021;
+Added: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021;
+Added: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021;
and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
3 unchanged sentences
REGENERON PHARMACEUTICALS, INC.
−Removed: August 3, 2022 By:
+Added: November 3, 2022 By:
/s/ Robert E.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.